Published Date: 02 Mar 2023
Sports activities promote bone healing by interfering with substances that stimulate osteoblasts.
Read Full NewsHome visits — once common and now resurging — flip the dynamic, as the clinician becomes a guest in the patient's home. Experts say as both learn more about each other than is possible in-office, trust can build.
Higher body fat percentage, rather than BMI, is associated with reduced sperm count and disrupted reproductive hormone levels in men.
Standard TKI doses are often too high for long-term care. Dr Mark Kris shares his strategy for smart dose reductions that protect patient outcomes.
Cure rates are climbing, and so is the complexity of getting there. Dr Yara Abdou takes a closer look at optimizing HER2+ early-stage breast cancer therapy.
Direct primary care is more than medicine. Dr Rajdeep Dhami shares what physicians should know before starting DPC, from operations and branding to boundaries and community.
1.
In Advanced Myxoid Liposarcoma, Is Trabectedin Winning?
2.
Is Chemotherapy via Peripheral IV Access More Effective Than Central Lines for Testicular Cancer?
3.
Implant-based reconstruction linked to increased risk of breast lymphomas
4.
New Clues to Origin of T-Cell Lymphoma After CAR-T Therapy
5.
According to the Lancet, proton beam therapy may shorten the course of treatment for patients with breast cancer.
1.
Unlocking the Immune Arsenal: A Revolution in Cancer Treatment
2.
Blood Donation Sustainability Through Behavioral Science
3.
Navigating the Challenges of Vaso-Occlusive Crisis: A Guide for Patients and Caregivers
4.
Understanding Macrocytosis: Causes, Symptoms, and Treatment Options
5.
Case Study: Genomic Medicine in Precision Oncology
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part I
2.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
3.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
4.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VII
5.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Conclusion
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation